| Name | Title | Contact Details |
|---|
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
BioElectron is a platform biotechnology company, with expertise in the electron transfer (redox) chemical reactions that underpin oxidative stress and inflammation in all biological systems.
CE and IC Inc is a Burlington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mammotome is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NextImage Medical, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.